U.S. Markets closed

Adamis Pharmaceuticals Corporation (ADMP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8142-0.0347 (-4.09%)
At close: 4:00PM EDT

0.8002 -0.01 (-1.72%)
After hours: 7:59PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8489
Open0.8478
Bid0.8002 x 1200
Ask0.8199 x 900
Day's Range0.7600 - 0.8499
52 Week Range0.3200 - 2.3400
Volume5,595,858
Avg. Volume19,816,591
Market Cap114.215M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Adamis Pharma To Resubmit Zimhi US Application For Opioid Overdose Soon
    Benzinga

    Adamis Pharma To Resubmit Zimhi US Application For Opioid Overdose Soon

    Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has provided an update on its marketing application's status seeking approval for Zimhi's high-dose naloxone injection product to treat opioid overdose. Type A meeting with the FDA was concluded. The company believes the meeting was productive and plans to resubmit the Zimhi application to the FDA within the next 45 days, absent unexpected delays. The FDA did not provide a detailed timeline for review but did indicate that it would attempt to work expeditiously. Last year, the company received a complete response letter from the agency regarding the Zimhi marketing application. The questions raised by the FDA are generally related to new Chemistry, Manufacturing, and Controls issues. Naloxone is an opioid antagonist and is generally considered the drug of choice for immediate administration for opioid overdose. It works by blocking or reversing the effects of the opioid, including extreme drowsiness, slowed breathing, or loss of consciousness. Price Action: ADMP shares are down 1.3% at $0.87 on the last check Monday. See more from BenzingaClick here for options trades from BenzingaOncolytics Biotech's Pelareorep Associated With Therapeutic Efficacy, Improved Clinical Outcomes In Breast CancerCardiff Oncology's Onvansertib Shows Durable Response, Progression-Free Survival In Colorectal Cancer Patients© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Will Adamis Pharmaceuticals (ADMP) Report Negative Q4 Earnings? What You Should Know
    Zacks

    Will Adamis Pharmaceuticals (ADMP) Report Negative Q4 Earnings? What You Should Know

    Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Benzinga

    Adamis Pharma Shares Fall Despite US Patent Covering Naloxone

    U.S. Patent and Trademark Office has allowed a patent to one of the patent applications by Adamis Pharmaceuticals Corp (NASDAQ: ADMP) related to its ZIMHI high-dose naloxone injection product candidate, intended for opioid overdose. The allowed claims comprise a naloxone composition at a dose greater than or equal to five milligrams configured for administration as an injection. "Our 5 mg dose of naloxone delivered by intramuscular or subcutaneous injection has demonstrated significantly higher availability (naloxone in the blood) at 2.5 and 5 minutes (critical period) when compared to the current FDA-approved product", said Dr. Dennis J. Carlo, President, and CEO. Last year, the company received an FDA response letter for the ZIMHI application for opioid overdose, citing Chemistry, Manufacturing, and Controls issues. The company says it looks forward to meeting with the FDA to discuss the responses submitted to the agency's response letter for ZIMHI. Price Action: ADMP stock is down 7.01% at $1.46 in market trading hours on last check Wednesday. See more from BenzingaClick here for options trades from BenzingaNascent Biotech Gains On Encouraging Pritumumab Data From Preclinical StudiesSalarius Moves Forward With Seclidemstat Study In Soft Tissue Cancer; Shares Spike© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.